Oulu, Finland, November 29, 2022 –(PR.com)– “It is very encouraging when appreciation comes to Paras Biopharmaceuticals, especially from a USA-based company that is very innovative in its work and is developing challenging next generation biologics. Paras Biopharmaceuticals proudly shares its recommendation and appreciation of its USA-based customer who we served in 2021/2022,” says Dr. Mark Jackson, Administration Lead of Paras Biopharmaceuticals.

Recommendation from a Biotech company in the San Francisco Bay area, USA – Director, CMC/Pharmaceutical Development

“Paras Biopharmaceuticals is a solid company to generate pilot-scale material with high quality. The scientists at Paras Biopharmaceuticals’ upstream, downstream, and analytical groups are experienced in process operation and analytical assay transfer. The project manager and technical lead are responsible and well-organised. When we initiate our project with a…